drugset
drugset / Trial / NCT00246012

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012 ↗

Phase 1/2 Completed 144 enrolled Centocor, Inc. Janssen-Cilag Farmaceutica, S.R.L. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of the intetumumab, alone and in combination with dacarbazine, in patients with stage 4 melanoma.

Timeline

Start
2005-05
Primary completion
2008-06
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 1000 mg/m2 Intravenous
Subject Intetumumab Monoclonal antibody 3 mg/kg Intravenous
Subject Intetumumab Monoclonal antibody 5 mg/kg Intravenous
Subject Intetumumab Monoclonal antibody 10 mg/kg Intravenous

Indications

melanoma